Esperion(US:ESPR) Globenewswire·2026-03-30 12:00Core Insights - Esperion announced two post-hoc analyses from the CLEAR Outcomes trial, demonstrating a 22% reduced risk of ischemic stroke for patients taking bempedoic acid compared to placebo [1][5] - The analyses also indicated that bempedoic acid reduced major adverse cardiovascular events (MACE) in high-risk patients with autoimmune or inflammatory diseases similarly to those without such conditions [1][5] Group 1: Clinical Findings - Bempedoic acid reduced the risk of ischemic stroke by 22% compared to placebo, with 90% of the 293 strokes recorded being ischemic [5] - Approximately 10% of the 13,970 participants in the CLEAR Outcomes trial had prior autoimmune and inflammatory diseases, which increase the risk of MACE [5] - Patients with autoimmune or inflammatory diseases experienced similar clinical benefits from bempedoic acid as those without these conditions [5] Group 2: Expert Commentary - Dr. Luke Laffin emphasized the elevated cardiovascular burden faced by patients with autoimmune and inflammatory diseases, highlighting the meaningful reductions in cardiovascular events provided by bempedoic acid [2] - Sheldon Koenig, President and CEO of Esperion, noted that the findings strengthen the evidence base for NEXLETOL as a therapy for cardiovascular risk reduction, particularly for statin-intolerant patients [2] Group 3: Product Indications - NEXLIZET and NEXLETOL are indicated to reduce the risk of major adverse cardiovascular events in adults at increased risk who cannot take statin therapy [5][6] - Bempedoic acid is part of these therapies aimed at lowering LDL-C levels in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH) [5][6]